CA2566578A1 - Systeme et procede de gestion de remodelisation cardiaque nocive - Google Patents
Systeme et procede de gestion de remodelisation cardiaque nocive Download PDFInfo
- Publication number
- CA2566578A1 CA2566578A1 CA002566578A CA2566578A CA2566578A1 CA 2566578 A1 CA2566578 A1 CA 2566578A1 CA 002566578 A CA002566578 A CA 002566578A CA 2566578 A CA2566578 A CA 2566578A CA 2566578 A1 CA2566578 A1 CA 2566578A1
- Authority
- CA
- Canada
- Prior art keywords
- phase
- stimulation
- heart
- electrodes
- cardiac remodeling
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000007634 remodeling Methods 0.000 title claims abstract description 60
- 230000000747 cardiac effect Effects 0.000 title claims abstract description 48
- 238000000034 method Methods 0.000 title claims abstract description 22
- 230000001627 detrimental effect Effects 0.000 title description 6
- 230000000638 stimulation Effects 0.000 claims abstract description 147
- 210000002216 heart Anatomy 0.000 claims abstract description 112
- 210000005003 heart tissue Anatomy 0.000 claims abstract description 59
- 230000002861 ventricular Effects 0.000 claims abstract description 47
- 210000000130 stem cell Anatomy 0.000 claims abstract description 36
- 230000001010 compromised effect Effects 0.000 claims abstract description 25
- 208000010125 myocardial infarction Diseases 0.000 claims description 56
- 210000005240 left ventricle Anatomy 0.000 claims description 53
- 230000002051 biphasic effect Effects 0.000 claims description 37
- 230000002763 arrhythmic effect Effects 0.000 claims description 31
- 230000002964 excitative effect Effects 0.000 claims description 25
- 210000004165 myocardium Anatomy 0.000 claims description 23
- 210000001992 atrioventricular node Anatomy 0.000 claims description 19
- 230000005284 excitation Effects 0.000 claims description 10
- 230000004044 response Effects 0.000 claims description 9
- 210000005242 cardiac chamber Anatomy 0.000 claims description 4
- 230000036279 refractory period Effects 0.000 claims description 2
- 238000005086 pumping Methods 0.000 abstract description 8
- 230000022900 cardiac muscle contraction Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000008929 regeneration Effects 0.000 abstract 1
- 238000011069 regeneration method Methods 0.000 abstract 1
- 210000005241 right ventricle Anatomy 0.000 description 39
- 210000001519 tissue Anatomy 0.000 description 33
- 239000008280 blood Substances 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 22
- 206010019280 Heart failures Diseases 0.000 description 19
- 230000008602 contraction Effects 0.000 description 13
- 230000006378 damage Effects 0.000 description 11
- 206010003119 arrhythmia Diseases 0.000 description 10
- 230000006793 arrhythmia Effects 0.000 description 10
- 210000002837 heart atrium Anatomy 0.000 description 10
- 238000002560 therapeutic procedure Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 7
- 208000019622 heart disease Diseases 0.000 description 7
- 206010020880 Hypertrophy Diseases 0.000 description 6
- 230000001746 atrial effect Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000002513 implantation Methods 0.000 description 6
- 210000005245 right atrium Anatomy 0.000 description 6
- 230000002411 adverse Effects 0.000 description 5
- 230000003205 diastolic effect Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 206010061216 Infarction Diseases 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 238000010009 beating Methods 0.000 description 4
- 230000036471 bradycardia Effects 0.000 description 4
- 208000006218 bradycardia Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 210000004351 coronary vessel Anatomy 0.000 description 4
- 230000010339 dilation Effects 0.000 description 4
- 210000005246 left atrium Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000004118 muscle contraction Effects 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 206010003673 Atrioventricular block complete Diseases 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 206010000891 acute myocardial infarction Diseases 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000002876 beta blocker Substances 0.000 description 3
- 229940097320 beta blocking agent Drugs 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 208000027744 congestion Diseases 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000007574 infarction Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000028161 membrane depolarization Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000036316 preload Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 201000002931 third-degree atrioventricular block Diseases 0.000 description 3
- 239000005541 ACE inhibitor Substances 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 206010008469 Chest discomfort Diseases 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 206010016803 Fluid overload Diseases 0.000 description 2
- 206010042434 Sudden death Diseases 0.000 description 2
- 208000033774 Ventricular Remodeling Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 230000003288 anthiarrhythmic effect Effects 0.000 description 2
- 239000003416 antiarrhythmic agent Substances 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 210000004375 bundle of his Anatomy 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 238000009125 cardiac resynchronization therapy Methods 0.000 description 2
- 230000001447 compensatory effect Effects 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000010247 heart contraction Effects 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000005244 lower chamber Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 210000000107 myocyte Anatomy 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 210000003492 pulmonary vein Anatomy 0.000 description 2
- 230000034225 regulation of ventricular cardiomyocyte membrane depolarization Effects 0.000 description 2
- 238000009168 stem cell therapy Methods 0.000 description 2
- 238000009580 stem-cell therapy Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 208000003663 ventricular fibrillation Diseases 0.000 description 2
- 206010047302 ventricular tachycardia Diseases 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
- 206010001115 Adams-Stokes syndrome Diseases 0.000 description 1
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 206010003662 Atrial flutter Diseases 0.000 description 1
- 206010006578 Bundle-Branch Block Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010052337 Diastolic dysfunction Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 208000029422 Hypernatremia Diseases 0.000 description 1
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010028311 Muscle hypertrophy Diseases 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 206010040639 Sick sinus syndrome Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 208000007888 Sinus Tachycardia Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
- 206010071436 Systolic dysfunction Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 208000009729 Ventricular Premature Complexes Diseases 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- 206010068767 Viral cardiomyopathy Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 210000001765 aortic valve Anatomy 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000003683 cardiac damage Effects 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 208000022368 idiopathic cardiomyopathy Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000000297 inotrophic effect Effects 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- WABPQHHGFIMREM-VENIDDJXSA-N lead-201 Chemical compound [201Pb] WABPQHHGFIMREM-VENIDDJXSA-N 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 208000005907 mitral valve insufficiency Diseases 0.000 description 1
- 230000012042 muscle hypertrophy Effects 0.000 description 1
- 230000000661 pacemaking effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 238000000306 qrs interval Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 208000037905 systemic hypertension Diseases 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 210000000591 tricuspid valve Anatomy 0.000 description 1
- 210000005243 upper chamber Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000000596 ventricular septum Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
- A61N1/3627—Heart stimulators for treating a mechanical deficiency of the heart, e.g. congestive heart failure or cardiomyopathy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
- A61N1/365—Heart stimulators controlled by a physiological parameter, e.g. heart potential
- A61N1/36592—Heart stimulators controlled by a physiological parameter, e.g. heart potential controlled by the heart rate variability
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
- A61N1/365—Heart stimulators controlled by a physiological parameter, e.g. heart potential
- A61N1/368—Heart stimulators controlled by a physiological parameter, e.g. heart potential comprising more than one electrode co-operating with different heart regions
- A61N1/3684—Heart stimulators controlled by a physiological parameter, e.g. heart potential comprising more than one electrode co-operating with different heart regions for stimulating the heart at multiple sites of the ventricle or the atrium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
- A61N1/365—Heart stimulators controlled by a physiological parameter, e.g. heart potential
- A61N1/368—Heart stimulators controlled by a physiological parameter, e.g. heart potential comprising more than one electrode co-operating with different heart regions
- A61N1/3684—Heart stimulators controlled by a physiological parameter, e.g. heart potential comprising more than one electrode co-operating with different heart regions for stimulating the heart at multiple sites of the ventricle or the atrium
- A61N1/36842—Multi-site stimulation in the same chamber
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
- A61N1/365—Heart stimulators controlled by a physiological parameter, e.g. heart potential
- A61N1/368—Heart stimulators controlled by a physiological parameter, e.g. heart potential comprising more than one electrode co-operating with different heart regions
- A61N1/3684—Heart stimulators controlled by a physiological parameter, e.g. heart potential comprising more than one electrode co-operating with different heart regions for stimulating the heart at multiple sites of the ventricle or the atrium
- A61N1/36843—Bi-ventricular stimulation
Landscapes
- Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Electrotherapy Devices (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57512104P | 2004-05-28 | 2004-05-28 | |
| US60/575,121 | 2004-05-28 | ||
| PCT/US2005/019089 WO2005118062A2 (fr) | 2004-05-28 | 2005-05-31 | Système et procédé de gestion de remodélisation cardiaque nocive |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2566578A1 true CA2566578A1 (fr) | 2005-12-15 |
Family
ID=35463374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002566578A Abandoned CA2566578A1 (fr) | 2004-05-28 | 2005-05-31 | Systeme et procede de gestion de remodelisation cardiaque nocive |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1753501A4 (fr) |
| JP (1) | JP2008500883A (fr) |
| KR (1) | KR20070062455A (fr) |
| CN (1) | CN101076369A (fr) |
| AU (1) | AU2005250010A1 (fr) |
| CA (1) | CA2566578A1 (fr) |
| IL (1) | IL179649A0 (fr) |
| MX (1) | MXPA06013845A (fr) |
| WO (1) | WO2005118062A2 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7787950B1 (en) | 2006-11-03 | 2010-08-31 | Pacesetter, Inc. | Techniques for delivery of stem cell and related therapies to treat cardiac conditions |
| US8694119B2 (en) * | 2009-05-14 | 2014-04-08 | Samson Neurosciences Ltd. | Endovascular electrostimulation near a carotid bifurcation in treating cerebrovascular conditions |
| CN102824197B (zh) * | 2012-09-21 | 2017-11-17 | 复旦大学附属华山医院 | 一种用于左心室的干细胞移植螺旋电极 |
| CN112292178A (zh) | 2018-06-14 | 2021-01-29 | 美敦力公司 | 用于心脏重塑的心脏起搏治疗的递送 |
| CN112292179A (zh) * | 2018-06-14 | 2021-01-29 | 美敦力公司 | 用于心脏重塑的心脏起搏治疗的递送 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5601612A (en) * | 1993-08-06 | 1997-02-11 | Heartstream, Inc. | Method for applying a multiphasic waveform |
| US6151525A (en) * | 1997-11-07 | 2000-11-21 | Medtronic, Inc. | Method and system for myocardial identifier repair |
| US6067470A (en) * | 1998-03-05 | 2000-05-23 | Mower Family Chf Treatment Irrevocable Trust | System and method for multiple site biphasic stimulation to revert ventricular arrhythmias |
| US6411845B1 (en) * | 1999-03-04 | 2002-06-25 | Mower Chf Treatment Irrevocable Trust | System for multiple site biphasic stimulation to revert ventricular arrhythmias |
| US20020124855A1 (en) * | 2001-03-12 | 2002-09-12 | Chachques Juan C. | Method of providing a dynamic cellular cardiac support |
| US6628988B2 (en) * | 2001-04-27 | 2003-09-30 | Cardiac Pacemakers, Inc. | Apparatus and method for reversal of myocardial remodeling with electrical stimulation |
| US6965797B2 (en) * | 2002-09-13 | 2005-11-15 | Cardiac Pacemakers, Inc. | Method and apparatus for assessing and treating myocardial wall stress |
-
2005
- 2005-05-31 WO PCT/US2005/019089 patent/WO2005118062A2/fr active Application Filing
- 2005-05-31 JP JP2007515490A patent/JP2008500883A/ja active Pending
- 2005-05-31 CN CNA2005800251776A patent/CN101076369A/zh active Pending
- 2005-05-31 KR KR1020067027594A patent/KR20070062455A/ko not_active Application Discontinuation
- 2005-05-31 CA CA002566578A patent/CA2566578A1/fr not_active Abandoned
- 2005-05-31 EP EP05756496A patent/EP1753501A4/fr not_active Withdrawn
- 2005-05-31 MX MXPA06013845A patent/MXPA06013845A/es not_active Application Discontinuation
- 2005-05-31 AU AU2005250010A patent/AU2005250010A1/en not_active Abandoned
-
2006
- 2006-11-28 IL IL179649A patent/IL179649A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005118062A2 (fr) | 2005-12-15 |
| IL179649A0 (en) | 2007-05-15 |
| EP1753501A2 (fr) | 2007-02-21 |
| JP2008500883A (ja) | 2008-01-17 |
| EP1753501A4 (fr) | 2008-01-23 |
| CN101076369A (zh) | 2007-11-21 |
| WO2005118062A3 (fr) | 2007-04-12 |
| MXPA06013845A (es) | 2007-04-16 |
| AU2005250010A1 (en) | 2005-12-15 |
| KR20070062455A (ko) | 2007-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7440800B2 (en) | System and method for managing detrimental cardiac remodeling | |
| US8447399B2 (en) | System and method for managing detrimental cardiac remodeling | |
| US11529520B2 (en) | Methods and apparatus to stimulate heart atria | |
| US7103410B2 (en) | Apparatus and method for reversal of myocardial remodeling with electrical stimulation | |
| US7725185B2 (en) | Cardiac stimulation at high ventricular wall stress areas | |
| US20220088384A1 (en) | Method and apparatus for intrachamber resynchronization | |
| WO2005011802A2 (fr) | Optimisation d'intervalle mecanique pour moteur de synchronisation biventriculaire | |
| CA2566578A1 (fr) | Systeme et procede de gestion de remodelisation cardiaque nocive | |
| US9943692B2 (en) | System and method for stimulating the heart in combination with cardiac rhythm management pharmaceuticals | |
| Sweeney | Cardiac resynchronization therapy | |
| Civelek et al. | Ýleri Kalp Yetmezliði Tedavisinde Kardiyak Resenkronizasyon: Alternatif Bir Tedavi mi? | |
| Rho et al. | Current Concepts of Biventricular Pacing in Heart Failure | |
| Rho et al. | 17 Current Concepts of Biventricular |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20150512 |